Use the title search or filter to quickly find relevant clinical guidance and provide clinical care according to the best available evidence.

June 2023
Committee Statement

Standardization of abortion nomenclature and terms used to refer to different types of abortion will increase uniformity and accuracy in communication about abortion care. The Society of Family Planning’s recommendation is to use the terms medication abortion and procedural abortion for common use in clinical guidance, journal articles, print materials, websites, media, advocacy, policy briefs, ... Read more >

January 2023
Clinical Recommendation

Emergency contraception (EC) refers to several contraceptive options that can be used within a few days after unprotected or under protected intercourse or sexual assault to reduce the risk of pregnancy. Current EC options available in the United States include the copper intrauterine device (IUD), levonorgestrel (LNG) 52 mg IUD, oral LNG (such as Plan ... Read more >

September 2022
Interim Clinical Recommendation

This document is currently under revision. Clinical guidance is rigorously developed to reflect the best available evidence at the time of publication. It is designed as a resource to assist clinicians in providing family planning care. It is not intended to substitute for the independent professional judgment of the treating clinician. We recognize that continued ... Read more >

July 2022
Committee Consensus

Historical evidence that fetal red blood cell (RBC) exposure during early spontaneous or induced abortion can cause maternal Rh sensitization is limited. A close reading of these studies indicates that forgoing Rh immunoglobulin administration before 12 weeks gestation is highly unlikely to increase risk of Rh (D) antibody development, and recent studies indicate that fetal ... Read more >

June 2022
Clinical Recommendation

In this clinical recommendation, we review the evidence supporting the use of the copper intrauterine device, levonorgestrel intrauterine devices and etonogestrel subdermal implant beyond the Food and Drug Administration approved duration of use for contraception (extended use). Clinicians should discuss effectiveness as well as other clinical considerations with patients to allow them to make contraceptive ... Read more >